1 BTC
=
- USD
Alpha Tau Medical Ltd. Ordinary Shares
As of May 30, 2026 at 24:05 UTC
Chart
About Alpha Tau Medical Ltd. Ordinary Shares
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Market Statistics
Trading Metrics
How to Buy DRTS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy DRTS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesAlpha Tau Medical Ltd. announced the completion of enrollment of 88 patients in its ReSTART pivotal trial for treating recurrent cutaneous squamous cell carcinoma (cSCC) with Alpha DaRT®. This marks the company's first completed U.S. pivotal study and a critical milestone toward FDA pre-market approval. The company has already initiated a modular PMA application process. Alpha DaRT has received Breakthrough Device Designation from the FDA for this indication.
The global radiopharmaceuticals market is projected to grow at a CAGR of 10.3% from 2024 to 2030, driven by the increasing prevalence of chronic diseases, advancements in imaging technology, and the transition towards personalized medicine. North America and Asia-Pacific are the key regional markets.
